Table 4.

Relationship between mutations and clinical response

Usage/Dose	Best Response	GCB Subtype	CARD11	CD79A	CD79B	MYD88	ORR‡
320 mg	PD	NGC	F115I	WT	WT	WT	57% (4/7)
320 mg	PR	GCB	D200N	WT	WT	WT
480 mg, fasted	PD	GCB	D224N	WT	WT	WT
480 mg, fasted	SD	NGC	M275I	WT	WT	WT
480 mg, fasted	PR	NGC	N255D	WT	WT	WT
480 mg, fasted	PR	NGC	E185A	WT	WT	WT
480 mg	PR	NGC	F130L	WT	WT	WT
480 mg, fasted	PD	NGC	E185A	WT	Y196H	L265P	33% (2/6)
480 mg, fasted	PD	NGC	E185A	WT	A188G/E224D	L265P
480 mg, fasted	PD	GCB	Q48*	G167S/L168F	Y196C/D202N	L265P/K269E
480 mg, fasted	SD	NGC	E185A	WT	Y196S	L265P
480 mg, fasted	CRu	NGC	C49Y	WT	E229K	Q262*
480 mg, fasted	CRu	GCB	E185A	WT	Y196H	L265P

CRu, unconfirmed complete response; GCB, germinal center-B-cell; NGC, non-germinal center subtype; PR, partial response; SD, stable disease; PD, progressive disease; WT, wild type.

^‡ORR was defined as the percentage of patients (number of patients with response/treated).